Other
High Impact Clinical Research Support Program
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.4% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Phase 2
1(33.3%)
Early Phase 1
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 2(1)
Early Phase 1(1)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT02113657Early Phase 1Completed
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
Role: collaborator
NCT01630590Phase 2Completed
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Role: collaborator
NCT02652871Phase 1Completed
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Role: collaborator
All 3 trials loaded